Northern Trust Corp Ovid Therapeutics Inc. Transaction History

Northern Trust Corp

  • $690 Billion
  • Q4 2024

A detailed history of Northern Trust Corp transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Northern Trust Corp holds 488,171 shares of OVID stock, worth $239,203. This represents 0.0% of its overall portfolio holdings.

Number of Shares
488,171
Previous 480,225 1.65%
Holding current value
$239,203
Previous $566,000 19.96%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$0.93 - $1.36 $7,389 - $10,806
7,946 Added 1.65%
488,171 $453,000
Q3 2024

Nov 13, 2024
BUY
$0.75 - $1.3 $11,019 - $19,100
14,693 Added 3.16%
480,225 $566,000
Q2 2024

Aug 14, 2024
SELL
$0.7 - $3.34 $10,734 - $51,218
-15,335 Reduced 3.19%
465,532 $358,000
Q1 2024

May 14, 2024
SELL
$2.72 - $4.04 $26,669 - $39,612
-9,805 Reduced 2.0%
480,867 $1.47 Million
Q4 2023

Feb 13, 2024
BUY
$2.98 - $3.78 $35,348 - $44,838
11,862 Added 2.48%
490,672 $1.58 Million
Q3 2023

Nov 13, 2023
SELL
$3.23 - $3.97 $6,437 - $7,912
-1,993 Reduced 0.41%
478,810 $1.84 Million
Q2 2023

Aug 11, 2023
BUY
$2.53 - $3.89 $941,542 - $1.45 Million
372,151 Added 342.52%
480,803 $1.58 Million
Q1 2023

May 15, 2023
BUY
$1.88 - $2.85 $21,296 - $32,284
11,328 Added 11.64%
108,652 $280,000
Q4 2022

Feb 13, 2023
SELL
$1.43 - $1.89 $14 - $18
-10 Reduced 0.01%
97,324 $181,000
Q3 2022

Nov 14, 2022
BUY
$1.84 - $2.26 $25,982 - $31,913
14,121 Added 16.97%
97,334 $179,000
Q2 2022

Aug 12, 2022
SELL
$1.69 - $3.31 $790 - $1,549
-468 Reduced 0.56%
83,213 $179,000
Q1 2022

May 13, 2022
SELL
$2.65 - $3.49 $9,396 - $12,375
-3,546 Reduced 4.07%
83,681 $263,000
Q3 2021

Nov 15, 2021
BUY
$3.31 - $4.04 $17,129 - $20,907
5,175 Added 6.31%
87,227 $293,000
Q2 2021

Aug 13, 2021
SELL
$3.3 - $4.49 $1.32 Million - $1.8 Million
-399,811 Reduced 82.97%
82,052 $321,000
Q1 2021

May 12, 2021
SELL
$2.42 - $4.47 $46,914 - $86,655
-19,386 Reduced 3.87%
481,863 $1.94 Million
Q4 2020

Feb 11, 2021
BUY
$2.28 - $6.84 $38,737 - $116,211
16,990 Added 3.51%
501,249 $1.16 Million
Q3 2020

Nov 16, 2020
SELL
$5.39 - $8.24 $114,418 - $174,918
-21,228 Reduced 4.2%
484,259 $2.78 Million
Q2 2020

Aug 14, 2020
BUY
$2.67 - $7.91 $1.16 Million - $3.45 Million
435,638 Added 623.69%
505,487 $3.73 Million
Q1 2020

May 14, 2020
BUY
$2.03 - $4.35 $38,626 - $82,771
19,028 Added 37.44%
69,849 $209,000
Q4 2019

Feb 14, 2020
SELL
$2.08 - $5.06 $16,421 - $39,948
-7,895 Reduced 13.45%
50,821 $211,000
Q3 2019

Nov 13, 2019
SELL
$1.76 - $3.51 $214,324 - $427,430
-121,775 Reduced 67.47%
58,716 $190,000
Q2 2019

Aug 13, 2019
SELL
$1.59 - $2.14 $14,088 - $18,962
-8,861 Reduced 4.68%
180,491 $334,000
Q1 2019

May 13, 2019
BUY
$1.77 - $3.56 $89,351 - $179,712
50,481 Added 36.35%
189,352 $336,000
Q4 2018

Feb 12, 2019
SELL
$2.42 - $6.6 $6,926 - $18,889
-2,862 Reduced 2.02%
138,871 $336,000
Q3 2018

Nov 14, 2018
BUY
$5.6 - $11.0 $68,521 - $134,596
12,236 Added 9.45%
141,733 $804,000
Q2 2018

Sep 18, 2018
SELL
$6.16 - $10.14 $9,868 - $16,244
-1,602 Reduced 1.22%
129,497 $1.01 Million
Q2 2018

Aug 14, 2018
BUY
$6.16 - $10.14 $78,041 - $128,463
12,669 Added 10.7%
131,099 $1.02 Million
Q1 2018

May 09, 2018
BUY
$6.53 - $9.82 $347,813 - $523,052
53,264 Added 81.74%
118,430 $837,000
Q4 2017

Feb 14, 2018
BUY
$6.12 - $12.31 $46,628 - $93,789
7,619 Added 13.24%
65,166 $643,000
Q3 2017

Nov 13, 2017
BUY
$5.32 - $9.77 $306,150 - $562,234
57,547
57,547 $493,000

Others Institutions Holding OVID

# of Institutions
82
Shares Held
40.7M
Call Options Held
2.4K
Put Options Held
200
View Full List

About Ovid Therapeutics Inc.

OVID Quotes by TradingView
  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $34.5M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email